In honor of America’s birthday, “Fast Money” traders pick companies to own that could be around for the next 239 years.» Read More
The strong dollar will impact earnings, the key is knowing what companies will weather the storm best, two experts said.
Jim Cramer takes a deep dive into this speculative pizza stock that's on fire.
Biotech hits a new record. A look at a disturbing biotech chart, with CNBC's Melissa Lee and the Options Action traders.
What has been the impact of the book?
Bonds, gold and oil go crazy. Can stocks stay calm? Volatility spreads beyond stocks, with CNBC's Melissa Lee and the Options Action traders.
How much more room does Facebook have to grow? CNBC's "Power Lunch" on Friday asked a bear and a bull for their takes.
Strategist Stacey Gilbert explains how to use a simple options strategy to play for further upside in small caps.
As the biotech sector and names such as Biogen continue to surge, finding value is becoming increasingly difficult, an expert says.
The best of #badhedgefundnames, which trended on Twitter Friday.
Karen Finerman gives her best way to play Michael Kors.
Some traders are betting that Taiwan Semiconductor's run is over.
CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.
CNBC's Jim Cramer says Tiffany's current business model doesn't work. Here's why.
BlackRock's chief investment strategist, said investors should keep eyeing the dollar as it's only on a "pause."
Commodities King Dennis Gartman says a combination of supply issues and a stronger dollar will cause a “stunning” decline for crude prices.
Shares of Nike were up 4 percent on Friday, and it's all about future orders, Michael Binetti tells CNBC.
The stronger dollar is a net-positive for the U.S. economy and the stock market, former Pimco managing director Paul McCulley tells CNBC.
Take a look at some of Friday's early movers:
History shows that after the Federal Reserve hikes rates for the first time, this happens to the stock market.
A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.